Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Bullboard Posts
Post by stockgurukingon Nov 13, 2012 1:57pm
255 Views
Post# 20594360

Interim Phase II Data Pending...

Interim Phase II Data Pending...

Based on the trial's official website (www.idealstudy.org) they will have full enrollment by the end of the year, this means that they very likely have a substantial number of patients enrolled already with the required 8 month follow up completed.  Meaning Interim Data is weeks away.  Looking back at the recent deals in the ophthalmic space tells me that mid and big Pharma is willing to pull the trigger on promising "early" data.

*

Many of you have already heard that iCo's partner, on a secondary asset (ICO-008), Immune Pharmaceuticals, has been planning a listing on a major US exchange and in conjunction with that a large raise ($20-30MM).  Well, last week Immune announced a definitive agremeement to list on the NASDAQ via a RTO.  The next step is raising the cash - which based on their engagement of ROTH Capital shouldn't be a problem.  ROTH has been an absolute power house in the Health Care space over the past couple of years.  Post RTO and without even raising the cash ICO's 6% ownership of Immune will be worth a minimum of $2MM.

 

Bullboard Posts